Candida haemulonii and closely related species at 5 university hospitals in Korea: Identification, antifungal susceptibility, and clinical features

Mi Na Kim, Jong Hee Shin, Heungsup Sung, Kyungwon Lee, Eui Chong Kim, Namhee Ryoo, Jin Sol Lee, Sook Ln Jung, Kyung Hwa Park, Seung Jung Kee, Soo Hyun Kim, Myung Geun Shin, Soon Pal Suh, Dong Wook Ryang

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background. Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human infection. During 2004-2006, unusual yeast isolates with phenotypic similarity to C, haemulonii were recovered from 23 patients (8 patients with fungemia and 15 patients with chronic otitis media) in 5 hospitals in Korea. Methods. Isolates were characterized using D1/D2 domain and ITS gene sequencing, and the susceptibility of the isolates to 6 antifungal agents was tested in vitro. Results. Gene sequencing of the blood isolates confirmed C. haemulonii group I (in 1 patient) and Candida pseudohaemulonii (in 7 patients), whereas all isolates recovered from the ear were a novel species of which C. haemulonii is its closest relative. The minimum inhibitory concentration (MIC) ranges of amphotericin B, fluconazole, itraconazole, and voriconazole for all isolates were 0.5-32 μg/mL (MIC 50, 1 μg/mL), 2-128 μg/mL (MIC 50, 4 μg/mL), 0.125-4 μg/mL (MIC 50, 0.25 μg/mL), and 0.03-2 μg/mL (MIC 50, 0.06 μg/mL), respectively. All isolates were susceptible to caspofungin (MIC, 0.125-0.25 μg/mL) and micafungin (MIC, 0.03-0.06 μg/mL). All cases of fungemia occurred in patients with severe underlying diseases who had central venous catheters. Three patients developed breakthrough fungemia while receiving antifungal therapy, and amphotericin B therapeutic failure, which was associated with a high MIC of amphotericin B (32 μg/mL), was observed in 2 patients. Conclusions. Candida species that are closely related to C haemulonii are emerging sources of infection in Korea. These species show variable patterns of susceptibility to amphotericin B and azole antifungal agents.

Original languageEnglish
Pages (from-to)e57-e61
JournalClinical Infectious Diseases
Volume48
Issue number6
DOIs
Publication statusPublished - 2009 Mar 15

Fingerprint

Microbial Sensitivity Tests
Korea
Candida
Amphotericin B
Fungemia
Inhibitory Concentration 50
Antifungal Agents
caspofungin
Yeasts
Azoles
Itraconazole
Central Venous Catheters
Fluconazole
Otitis Media
Infection
Genes
Ear
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Kim, Mi Na ; Shin, Jong Hee ; Sung, Heungsup ; Lee, Kyungwon ; Kim, Eui Chong ; Ryoo, Namhee ; Lee, Jin Sol ; Jung, Sook Ln ; Park, Kyung Hwa ; Kee, Seung Jung ; Kim, Soo Hyun ; Shin, Myung Geun ; Suh, Soon Pal ; Ryang, Dong Wook. / Candida haemulonii and closely related species at 5 university hospitals in Korea : Identification, antifungal susceptibility, and clinical features. In: Clinical Infectious Diseases. 2009 ; Vol. 48, No. 6. pp. e57-e61.
@article{6ad02878dbea423dbec2ee42a8ccf970,
title = "Candida haemulonii and closely related species at 5 university hospitals in Korea: Identification, antifungal susceptibility, and clinical features",
abstract = "Background. Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human infection. During 2004-2006, unusual yeast isolates with phenotypic similarity to C, haemulonii were recovered from 23 patients (8 patients with fungemia and 15 patients with chronic otitis media) in 5 hospitals in Korea. Methods. Isolates were characterized using D1/D2 domain and ITS gene sequencing, and the susceptibility of the isolates to 6 antifungal agents was tested in vitro. Results. Gene sequencing of the blood isolates confirmed C. haemulonii group I (in 1 patient) and Candida pseudohaemulonii (in 7 patients), whereas all isolates recovered from the ear were a novel species of which C. haemulonii is its closest relative. The minimum inhibitory concentration (MIC) ranges of amphotericin B, fluconazole, itraconazole, and voriconazole for all isolates were 0.5-32 μg/mL (MIC 50, 1 μg/mL), 2-128 μg/mL (MIC 50, 4 μg/mL), 0.125-4 μg/mL (MIC 50, 0.25 μg/mL), and 0.03-2 μg/mL (MIC 50, 0.06 μg/mL), respectively. All isolates were susceptible to caspofungin (MIC, 0.125-0.25 μg/mL) and micafungin (MIC, 0.03-0.06 μg/mL). All cases of fungemia occurred in patients with severe underlying diseases who had central venous catheters. Three patients developed breakthrough fungemia while receiving antifungal therapy, and amphotericin B therapeutic failure, which was associated with a high MIC of amphotericin B (32 μg/mL), was observed in 2 patients. Conclusions. Candida species that are closely related to C haemulonii are emerging sources of infection in Korea. These species show variable patterns of susceptibility to amphotericin B and azole antifungal agents.",
author = "Kim, {Mi Na} and Shin, {Jong Hee} and Heungsup Sung and Kyungwon Lee and Kim, {Eui Chong} and Namhee Ryoo and Lee, {Jin Sol} and Jung, {Sook Ln} and Park, {Kyung Hwa} and Kee, {Seung Jung} and Kim, {Soo Hyun} and Shin, {Myung Geun} and Suh, {Soon Pal} and Ryang, {Dong Wook}",
year = "2009",
month = "3",
day = "15",
doi = "10.1086/597108",
language = "English",
volume = "48",
pages = "e57--e61",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

Kim, MN, Shin, JH, Sung, H, Lee, K, Kim, EC, Ryoo, N, Lee, JS, Jung, SL, Park, KH, Kee, SJ, Kim, SH, Shin, MG, Suh, SP & Ryang, DW 2009, 'Candida haemulonii and closely related species at 5 university hospitals in Korea: Identification, antifungal susceptibility, and clinical features', Clinical Infectious Diseases, vol. 48, no. 6, pp. e57-e61. https://doi.org/10.1086/597108

Candida haemulonii and closely related species at 5 university hospitals in Korea : Identification, antifungal susceptibility, and clinical features. / Kim, Mi Na; Shin, Jong Hee; Sung, Heungsup; Lee, Kyungwon; Kim, Eui Chong; Ryoo, Namhee; Lee, Jin Sol; Jung, Sook Ln; Park, Kyung Hwa; Kee, Seung Jung; Kim, Soo Hyun; Shin, Myung Geun; Suh, Soon Pal; Ryang, Dong Wook.

In: Clinical Infectious Diseases, Vol. 48, No. 6, 15.03.2009, p. e57-e61.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Candida haemulonii and closely related species at 5 university hospitals in Korea

T2 - Identification, antifungal susceptibility, and clinical features

AU - Kim, Mi Na

AU - Shin, Jong Hee

AU - Sung, Heungsup

AU - Lee, Kyungwon

AU - Kim, Eui Chong

AU - Ryoo, Namhee

AU - Lee, Jin Sol

AU - Jung, Sook Ln

AU - Park, Kyung Hwa

AU - Kee, Seung Jung

AU - Kim, Soo Hyun

AU - Shin, Myung Geun

AU - Suh, Soon Pal

AU - Ryang, Dong Wook

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Background. Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human infection. During 2004-2006, unusual yeast isolates with phenotypic similarity to C, haemulonii were recovered from 23 patients (8 patients with fungemia and 15 patients with chronic otitis media) in 5 hospitals in Korea. Methods. Isolates were characterized using D1/D2 domain and ITS gene sequencing, and the susceptibility of the isolates to 6 antifungal agents was tested in vitro. Results. Gene sequencing of the blood isolates confirmed C. haemulonii group I (in 1 patient) and Candida pseudohaemulonii (in 7 patients), whereas all isolates recovered from the ear were a novel species of which C. haemulonii is its closest relative. The minimum inhibitory concentration (MIC) ranges of amphotericin B, fluconazole, itraconazole, and voriconazole for all isolates were 0.5-32 μg/mL (MIC 50, 1 μg/mL), 2-128 μg/mL (MIC 50, 4 μg/mL), 0.125-4 μg/mL (MIC 50, 0.25 μg/mL), and 0.03-2 μg/mL (MIC 50, 0.06 μg/mL), respectively. All isolates were susceptible to caspofungin (MIC, 0.125-0.25 μg/mL) and micafungin (MIC, 0.03-0.06 μg/mL). All cases of fungemia occurred in patients with severe underlying diseases who had central venous catheters. Three patients developed breakthrough fungemia while receiving antifungal therapy, and amphotericin B therapeutic failure, which was associated with a high MIC of amphotericin B (32 μg/mL), was observed in 2 patients. Conclusions. Candida species that are closely related to C haemulonii are emerging sources of infection in Korea. These species show variable patterns of susceptibility to amphotericin B and azole antifungal agents.

AB - Background. Candida haemulonii, a yeast species that often exhibits antifungal resistance, rarely causes human infection. During 2004-2006, unusual yeast isolates with phenotypic similarity to C, haemulonii were recovered from 23 patients (8 patients with fungemia and 15 patients with chronic otitis media) in 5 hospitals in Korea. Methods. Isolates were characterized using D1/D2 domain and ITS gene sequencing, and the susceptibility of the isolates to 6 antifungal agents was tested in vitro. Results. Gene sequencing of the blood isolates confirmed C. haemulonii group I (in 1 patient) and Candida pseudohaemulonii (in 7 patients), whereas all isolates recovered from the ear were a novel species of which C. haemulonii is its closest relative. The minimum inhibitory concentration (MIC) ranges of amphotericin B, fluconazole, itraconazole, and voriconazole for all isolates were 0.5-32 μg/mL (MIC 50, 1 μg/mL), 2-128 μg/mL (MIC 50, 4 μg/mL), 0.125-4 μg/mL (MIC 50, 0.25 μg/mL), and 0.03-2 μg/mL (MIC 50, 0.06 μg/mL), respectively. All isolates were susceptible to caspofungin (MIC, 0.125-0.25 μg/mL) and micafungin (MIC, 0.03-0.06 μg/mL). All cases of fungemia occurred in patients with severe underlying diseases who had central venous catheters. Three patients developed breakthrough fungemia while receiving antifungal therapy, and amphotericin B therapeutic failure, which was associated with a high MIC of amphotericin B (32 μg/mL), was observed in 2 patients. Conclusions. Candida species that are closely related to C haemulonii are emerging sources of infection in Korea. These species show variable patterns of susceptibility to amphotericin B and azole antifungal agents.

UR - http://www.scopus.com/inward/record.url?scp=62449106111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449106111&partnerID=8YFLogxK

U2 - 10.1086/597108

DO - 10.1086/597108

M3 - Article

C2 - 19193113

AN - SCOPUS:62449106111

VL - 48

SP - e57-e61

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -